BackCoherent Overview
Coherent Corp

Coherent Target Price

See Coherent's analyst price targets ($420) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$295.98

Average Target Price

$423.8343.2% upside

6 analysts in the last 4 months

High: $448 | Low: $400

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-31Deutsche Bank$40035.1% upsideOpen
2026-08-13Stifel NicolausRuben Roy$42041.9% upsideOpen
2026-08-13Raymond James$44851.4% upsideOpen
2026-08-13NeedhamRyan Koontz$42041.9% upsideOpen
2026-08-13Jefferies$42041.9% upsideOpen
2026-07-02Raymond James$43547% upsideOpen
2026-05-07Morgan StanleyMeta Marshall$33011.5% upsideOpen
2026-05-07Northland Securities$23022.3% downsideOpen
2026-05-07Raymond James$37125.3% upsideOpen
2026-05-05Stifel Nicolaus$41239.2% upsideOpen
2026-05-01Redburn PartnersMike Harrison$45553.7% upsideOpen
2026-04-20Morgan Stanley$2902% downsideOpen
2026-02-23Morgan StanleyMeta Marshall$25015.5% downsideOpen
2026-02-05Northland SecuritiesTim Savageaux$17042.6% downsideOpen
2026-02-05Stifel Nicolaus$23520.6% downsideOpen
2026-02-05BarclaysTom O'Malley$23520.6% downsideOpen
2026-01-30Morgan StanleyMeta Marshall$19035.8% downsideOpen
2026-01-22Stifel NicolausRuben Roy$22025.7% downsideOpen
2026-01-22SusquehannaChristopher Rolland$23520.6% downsideOpen
2026-01-15BarclaysTom O'Malley$21527.4% downsideOpen
2025-12-17Morgan StanleyMeta Marshall$18039.2% downsideOpen
2025-12-05Raymond JamesSimon Leopold$21029% downsideOpen
2025-11-06Needham$19035.8% downsideOpen
2025-11-06Susquehanna$16045.9% downsideOpen
2025-11-06Morgan StanleyMeta Marshall$15049.3% downsideOpen
2025-10-22SusquehannaChristopher Rolland$15049.3% downsideOpen
2025-10-20BarclaysTom O'Malley$13554.4% downsideOpen
2025-10-10Morgan Stanley$12059.5% downsideOpen
2025-08-14BarclaysTom O'Malley$11062.8% downsideOpen
2025-08-04Morgan Stanley$9767.2% downsideOpen
2025-06-02Northland SecuritiesTim Savageaux$8571.3% downsideOpen
2025-03-24Raymond JamesStrong Buy$9169.3% downsideOpen
2024-11-07Loop Capital MarketsAnanda Baruah$12059.5% downsideOpen
2024-10-22Rosenblatt SecuritiesMike Genovese$10564.5% downsideOpen
2024-10-18B.Riley FinancialDave Kang$8670.9% downsideOpen
2024-10-14NeedhamJames Ricchiuti$12059.5% downsideOpen
2024-10-04Bank of America SecuritiesVivek Arya$10863.5% downsideOpen
2024-10-01SusquehannaChristopher Rolland$12059.5% downsideOpen
2024-08-16Craig-HallumRichard Shannon$8571.3% downsideOpen
2024-08-16NeedhamJames Ricchiuti$8471.6% downsideOpen
2024-08-16Rosenblatt SecuritiesMike Genovese$8471.6% downsideOpen
2024-08-15NeedhamAlex Henderson$7076.3% downsideOpen
2024-08-12Bank of America SecuritiesVivek Arya$7574.7% downsideOpen
2024-04-01B.Riley FinancialDave Kang$7774% downsideOpen
2024-04-01NeedhamJames Ricchiuti$7275.7% downsideOpen
2024-01-16BarclaysTom O'Malley$6079.7% downsideOpen
2023-12-15NeedhamJim Ricchiuti$5282.4% downsideOpen
2023-10-11NeedhamJames Ricchiuti$5083.1% downsideOpen
2023-06-20NeedhamJim Ricchiuti$6478.4% downsideOpen
2022-12-13Morgan Stanley$4584.8% downsideOpen

Coherent (COHR) FAQ

Coherent posts a target price of $420. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $420 for COHR means covering analysts, on average, see the stock 43.2% upside of $295.98 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for COHR's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Coherent's other metric pages and overview cover the third.

Judging Coherent against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $420 here, then scan peer and history charts to see if the gap is persistent.